Media-OutReach Newswire The Lancet Neurology publishes positive results of AFFiRiS' Phase 1 trial with PD01A in Parkinson’s disease patients
2023 VinFuture Special Prize Laureate Prof. Daniel Drucker: Ample room remains for innovation in GLP-1 therapies 2.